Test Code LABMDDNAONCOCYT DNA OncoPlus FFPE/Cytology
Specimen and Container/Tube
Specimen Type: Tumor Tissue
Preferred Specimen: FFPE Slides or Cytology Smear
Other Acceptable Specimens: not applicable
Appropriate specimens should contain >20% tumor cells and enough total cells to produce adequate DNA yield (typically >50,000 total cells (FFPE) or >2000 total cells (cytology smear)). Specimens with less than 20% tumor cells may be tested at the discretion of the attending molecular pathologist.
Volume
Minimum Volume: 10 slides (FFPE), 1 slide (Cytology Smear)
Unstained slides containing FFPE tissue are acceptable. At least 10 microtome sections of 5 micron thickness should be submitted for testing. One adequate cytology smear should be submitted for testing.
Specimen Stability
N/A
Collection Instructions
Collect specimen per standard laboratory collection procedures.
Specimen Handling and Transport Instructions
UCM Onsite Instructions: Collect specimen per standard collection procedured and send to the laboratory immediately.
Turnaround Time
Turnaround times are relative to the time the specimen is received in the testing laboratory section.
STAT Turnaround Time: n/a
Routine Turnaround Time: ≤14 days
Testing Schedule: M-F 7:00am-5:00pm
Clinical Indications
The OncoPlus panel is a universal cancer mutation, next generation sequencing (NGS) assay that has the capability to cover more than 1,005 cancer-related genes, of which 168 genes are clinically reported, for personalized assessments of both solid tumors and hematological malignancies. Additional reportable features include tumor mutational burden (TMB), microsatellite stability status, and copy number alterations.
Test Components
Genes analyzed for mutations and insertions/deletions (168): ABL1, AKT1, ALK, APC, ARID1A, ARID2, ASXL1, ATM, ATR, ATRX, AXL, B2M, BAP1, BCOR, BCORL1, BIRC3, BLM, BRAF, BRCA1, BRCA2, BTK, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CCNE1, CD274, CDH1, CDK4, CDK6, CDK12, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DICER1, DNMT3A, EGFR, ELOC, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA1, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3-3A, H3C2, H3C3, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDM6A, KDR, KEAP1, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MDM2, MET, MEN1, MLH1, MLH3, MPL, MRE11, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PAX5, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD50, RAD51, RB1, RET, ROS1, RUNX1, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SRSF2, STAG2, STAT3, STAT5B, STK11, TERT, TET2, TP53, TRAF7, TSC1, TSC2, U2AF1, VHL, WT1, ZRSR2
Genes analyzed for copy number variations (145 gene subset): ABL1, AKT1, ALK, APC, ARID1A, ARID2, ASXL1, ATM, ATR, AXL, B2M, BAP1, BIRC3, BLM, BRAF, BRCA1, BRCA2, CALR, CBL, CBLB, CCND1, CCND2, CCND3, CCNE1, CD274, CDH1, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, CXCR4, DAXX, DDR2, DDX41, DICER1, DNMT3A, EGFR, EP300, EPHA3, EPHA5, ERBB2, ERBB3, ERBB4, ERCC3, ESR1, ETV6, EZH2, FANCA, FAT3, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, GRIN2A, H3-3A, H3C2, H3C3, HNF1A, HRAS, IDH1, IDH2, IKZF1, ITPKB, JAK2, KDR, KIT, KMT2A, KRAS, MAP2K1, MAPK1, MDM2, MET, MLH1, MLH3, MPL, MRE11, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, PALB2, PBRM1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3R1, PLCG2, POLE, POT1, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51, RB1, RET, RUNX1, SDHB, SDHC, SDHD, SETBP1, SF3B1, SMAD4, SMARCB1, SMC3, SMO, SRSF2, STAT3, STAT5B, STK11, TERT, TET2, TP53, TSC1, TSC2, U2AF1, VHL, WT1
Genes analyzed for fusions/translocations (3): ALK, RET, and ROS1
CPT Codes
81450
Methodology
The test procedure involves DNA extraction and quantity/quality assessment, fragmentation and library preparation, followed by pooled capture targeting the desired genomic loci. Next generation sequencing (NGS) is performed on the Illumina platform and downstream analysis for quality control and detection of mutations is performed via custom-design bioinformatics pipelines on a HIPAA-compliant high performance computing system within the Center for Research Informatics (CRI).
Synonyms/Key Search Words
CNV, copy number, cancer, mutation, panel, NGS, NextGen, Sequencing, Gene
Additional Information
Appropriate specimens should contain >20% tumor cells and enough total cells to produce adequate DNA yield (typically >50,000 total cells). Specimens with less than 20% tumor cells may be tested at the discretion of the attending molecular pathologist.